Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

Ratziu, Vlad; Giral, Philippe; Munteanu, Mona; Messous, Djamila; Mercadier, Anne; Bernard, Maguy; Morra, Rachel; Imbert‐Bismut, Françoise; Bruckert, Éric; Poynard, Thierry

doi:10.1111/j.1365-2036.2006.03182.x

Cited by 54 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite their widespread use in clinical practice, noninvasive radiological modalities such as ultrasound, computerized tomography, and magnetic resonance imaging can accurately detect hepatic steatosis but are unable to distinguish NASH or the stage of fibrosis [7]. Although several serum markers of fibrosis or other noninvasive measures of liver elasticity have been developed [8,9], their role in the management of NASH remains unproven. This presents an urgent need for additional, serum-based, noninvasive diagnostic biomarkers for NASH.…”

Section: Introductionmentioning

confidence: 98%

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Cirrhosis is the end-stage of this reaction and it represents a major change in the tissue. Most of the conventional approaches for the assessment of liver disease rely on few biomarkers, which represent particular disease states and often are not sufficient for providing global biochemical characterization and definitive diagnosis (17)(18)(19)(20). Global metabolic profiles, which are affected by many physiological and pathological processes, may more accurately reflect the presence of a particular disease state.…”

Section: Introductionmentioning

confidence: 99%

Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

Monleνn

2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Among the different processes occurring during the evolution of liver disease, fibrosis has a predominant role. Liver fibrosis mechanisms are fairly constant irrespective of the underlying etiology. Cirrhosis is the end-stage of this reaction. Metabolic profiles, which are affected by many physiological and pathological processes, may provide further insight into the metabolic consequences of this severe liver disease. The aim of this study was to demonstrate the applicability of 1 H high resolution magic angle spinning (HR-MAS) NMR spectroscopy in the biochemical profile determination of human liver needle biopsy samples for the characterization of metabolic alterations related to the severity of liver disease. We recorded and analyzed HR-MAS spectra of 68 liver tissue samples obtained by needle biopsy from patients with chronic liver disease. Multivariate analysis was applied to these data to obtain discrimination patterns and to reveal relevant metabolites. The metabolic characterization of liver tissue from needle biopsies by HR-MAS NMR spectroscopy provided differential patterns for cirrhotic and non-cirrhotic chronic liver disease tissue. Metabolites closely related to the liver metabolism such as some fatty acids, glucose and amino acids show differences between the two groups. Phospholipid precursors, which have been previously correlated with hepatic lesions also show differences. Furthermore, the correlation between histologically assessed liver disease stages and the levels of the most discriminative metabolites show that liver dysfunction is present at the initial stages of chronic hepatic lesions. Overall, this work suggests that the additional information obtained by NMR metabolomics applied to needle biopsies of human liver may be useful for assessing metabolic alterations and liver dysfunction in chronic liver disease. IntroductionThe liver is among the most metabolically diverse organs of the body and is involved in many critical metabolic processes (1). One of its major roles is storing endogenous fuels of the body. In addition, the liver acts as a major distribution center for exogenous energy supplies. The liver may be affected by many pathological aggressions. Liver dysfunction results in a variety of clinical signs and symptoms. However, some of these pathologies pose a diagnostic challenge as many different diseases show similar clinical signs (2-4). Moreover, liver biopsy assessment involves some degree of complication because of the proliferation of different grading and staging schemes (5-7). Metabolic alterations produced by liver disease may help clinicians better characterize the disease. Among the different processes occurring during the evolution of liver disease, fibrosis takes a predominant role. Liver fibrosis is characterized by the replacement of liver tissue by fibrous scar tissue as well as regenerative nodules, leading to progressive loss of liver function and to altered liver metabolism (8-11). Liver fibrosis induction mechanisms are fairly constant irrespectivel...

show abstract

“…In recent years, many noninvasive tests, e.g., AST/ ALT ratio, AST/platelet ratio index, hyaluronic acid, YKL-40, N-terminal propeptide of type III collagen, FibroTest, SteatoTest, and NashTest (18)(19)(20)(21)(22)(23)(24)(25), have been evaluated in clinical practice to replace liver biopsy for the assessment of the degree of fibrosis in patients with chronic liver disease due either to chronic viral hepatitis or NASH. Besides these markers, transient elastography, 13C-caffeine breath test, and DNA sequencedbased serum protein glycomics have also been proposed for the evaluation of liver fibrosis in chronic liver diseases (26)(27)(28).…”

Section: Discussionmentioning

confidence: 99%

Serum prolidase enzyme activity and its relation to histopathological findings in patients with non‐alcoholic steatohepatitis

Horoz

Aslan

Bolukbas

et al. 2010

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The aim of this study was to investigate serum prolidase enzyme activity and to find out its association with liver biopsy specimens' histopathological findings in patients with nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. Thirty-six patients with biopsy-proven NASH and 29 healthy controls were enrolled. Serum prolidase enzyme activity was measured spectrophotometrically. Serum prolidase enzyme activity was significantly higher in patients with NASH than controls (P=0.016). A significant correlation was observed between serum prolidase enzyme activity and fibrosis score in patients with NASH (r=0.661, P<0.001). Serum prolidase activity seems to be correlated with the level of fibrosis. Monitoring serum prolidase activity may be a useful adjunctive tool in predicting liver fibrosis, especially in the absence of advanced fibrosis and other conditions, which may affect the interpretation of prolidase activity.

show abstract

Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

Cited by 54 publications

References 35 publications

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

Serum prolidase enzyme activity and its relation to histopathological findings in patients with non‐alcoholic steatohepatitis

Contact Info

Product

Resources

About